Association between Serum Amylase Level and Incidence of Type 2 Diabetes

Although chronic pancreatitis is a known predictor of type 2 diabetes mellitus (T2DM), no previous studies have determined whether serum amylase (AMY) could be a predictor of T2DM with consideration of fasting plasma glucose (FPG) and HbA1c. We analyzed a historical cohort of 2,238 individuals without T2DM who underwent health examinations on an annual basis with a mean follow-up period of 9.6 y. AMY was categorized into quartiles and a multivariate Cox model was used to estimate the hazard ratio for incident T2DM. During a 10-y follow-up, 228 individuals developed T2DM. Median and interquartile range of baseline AMY(IU/L) was 74(62-91). Baseline AMY was significantly lower for participants who developed T2D compared to those who did not (71(59-84) vs. 75(62-92), p Disclosure D. Ishii: None. K. Fujihara: None. M. Harada: None. M. Ishizawa: None. S. Kodama: None. K. Saito: None. Y. Mori: None. R. Yamamoto-Honda: None. Y. Arase: None. H. Sone: Research Support; Self; Novo Nordisk Inc., Eli Lilly and Company, MSD K.K., Chugai Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Development Center Asia, Pte. Ltd., Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Sanofi, Kowa Pharmaceuticals America, Inc., Eisai Inc..